8-K: Enanta's Zelicapavir Shows Positive Phase 2b RSV Data

Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for respiratory syncytial virus (RSV) in high-risk adults, supporting advancement to Phase 3.

Summary

• Enanta Pharmaceuticals reported positive topline data from its Phase 2b high-risk adults study of zelicapavir (formerly EDP-938) for the treatment of respiratory syncytial virus (RSV).
• The study, RSVHR, was a proof-of-concept trial involving 186 non-hospitalized adults at high risk for RSV complications, including those with COPD, congestive heart failure, asthma, or age over 65.
• Zelicapavir demonstrated a favorable safety profile, with adverse events similar to placebo and no treatment-related discontinuations.
• Patients treated with zelicapavir experienced faster complete symptom resolution across multiple RiiQTM measures, including up to 7.2 days faster for total RiiQTM in the HR3 population.
• A statistically significant 2-day faster median time to symptom improvement was observed by Patient Global Impression of Severity (PGI-S) in both the efficacy (p=0.0446) and HR3 (p=0.0465) populations.
• The zelicapavir group showed a lower hospitalization rate (1.7% vs. 5.0% for placebo) and no deaths, compared to one death in the placebo group.
• Robust antiviral effects were observed, including a larger viral load decline (0.6-0.7 log) and a greater proportion of patients with undetectable viral load at Day 5 (23.5% vs. 10.0% for placebo, p=0.0198).
• The median time to undetectable viral load was 4-5 days faster for zelicapavir-treated patients.
• While there was no effect on the primary endpoint of time to resolution of RSV LRTD symptoms to mild, the totality of data supports advancing zelicapavir into a Phase 3 study.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to statistically significant improvements in key secondary endpoints (PGI-S, complete symptom resolution), robust antiviral activity, and a lower hospitalization rate, which collectively de-risk the asset and support advancement to Phase 3, despite missing the specific primary endpoint definition.

Positives

• Zelicapavir exhibited a favorable safety profile, with adverse events similar to placebo and no treatment-related discontinuations or study withdrawals.
• Demonstrated faster complete symptom resolution across multiple RiiQTM measures, including up to 7.2 days faster for total RiiQTM in the HR3 population.
• Achieved a statistically significant 2-day faster median time to symptom improvement by PGI-S in both efficacy (p=0.0446) and HR3 (p=0.0465) populations, exceeding the ~1 day benchmark for approved antivirals.
• Showed a lower hospitalization rate (1.7% for zelicapavir vs. 5.0% for placebo) and no deaths in the zelicapavir group, compared to one death in the placebo group.
• Exhibited robust antiviral activity, including a larger viral load decline (0.6-0.7 log) and a greater proportion of patients with undetectable viral load at Day 5 (23.5% vs. 10.0% for placebo, p=0.0198).
• Faster median time to undetectable viral load (4-5 days shorter) for zelicapavir-treated patients.
• Data supports advancement of zelicapavir into a Phase 3 study for high-risk adults, identifying multiple potential registrational endpoints.

Negatives

• No effect was observed on the time to resolution of RSV symptoms to mild, including the primary endpoint (time to resolution of LRTD subset of symptoms to mild in the efficacy population).

Risks

• Forward-looking statements in the presentation are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors beyond the company's control.
• Any forward-looking statements may turn out to be inaccurate.
• Investors are cautioned not to place undue reliance on forward-looking statements.
• Risks are described or referred to in the 'Risk Factors' section of Enanta's most recent Annual Report on Form 10-K and other periodic reports filed with the SEC.

Future Outlook

Data from the Phase 2b study of zelicapavir supports its advancement into a Phase 3 study for high-risk adults. The company has identified multiple potential registrational endpoints for the Phase 3 trial, including time to complete resolution of all 13 RSV symptoms by RiiQTM, time to complete resolution of total 29-parameter RiiQTM, time to resolution of PGI-S, and hospitalization rate.

Management Comments

• Jay R. Luly, Ph.D., President and Chief Executive Officer, signed the report on behalf of Enanta Pharmaceuticals, Inc.

Industry Context

RSV represents a significant unmet medical need, particularly in high-risk populations such as the elderly and those with chronic heart or lung conditions, who experience higher viral loads and greater disease severity. The clinical trial results for zelicapavir, showing a 2-day faster symptom resolution by PGI-S, compare favorably to the ~1-day reduction demonstrated by other approved antivirals for SARS-CoV-2 and Influenza, suggesting a potentially competitive profile in the antiviral market.

Comparison to Industry Standards

• Clinically meaningful reduction in symptom duration of approximately 1 day has been demonstrated by multiple approved antivirals for other respiratory viruses, such as oseltamivir for influenza, ensitrelvir for SARS-CoV-2, and baloxavir marboxil for influenza.
• Zelicapavir demonstrated a 2-day faster median time to symptom resolution by PGI-S in high-risk adults, which is better than the ~1 day benchmark observed with these other antivirals.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 2b results and progression to Phase 3, potentially increasing the company's valuation and future revenue prospects.
• Patients: Potential for a new, effective treatment option for RSV, particularly for high-risk adults who currently have significant unmet medical needs.
• Healthcare Providers: Could gain a new therapeutic tool to manage RSV infections in vulnerable populations, potentially reducing hospitalizations and disease severity.

Next Steps

• Advance zelicapavir into a Phase 3 study for high-risk adults.
• Utilize identified potential registrational endpoints for the Phase 3 study, including time to complete resolution of all 13 RSV symptoms by RiiQTM, time to complete resolution of total 29-parameter RiiQTM, time to resolution of PGI-S, and hospitalization rate.

Key Dates

Recommendation

The positive topline data for zelicapavir in a Phase 2b study for RSV in high-risk adults, despite a nuanced primary endpoint outcome, demonstrates significant clinical benefits. The statistically significant improvement in PGI-S, faster complete symptom resolution, lower hospitalization rates, and robust antiviral effect in a population with high unmet medical need are compelling. The decision to advance to Phase 3 with clear registrational endpoints further de-risks the asset. This progress positions Enanta favorably in the competitive antiviral market, suggesting strong future growth potential.

Keywords

Zelicapavir, RSV, Respiratory Syncytial Virus, Phase 2b, Clinical Trial, Antiviral, High-Risk Adults, Enanta Pharmaceuticals, EDP-938, Biotechnology, Pharmaceuticals